Company Announcements

Block listing Interim Review

Source: RNS
RNS Number : 1725L
GlaxoSmithKline PLC
11 May 2022
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 11 May 2022

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 November 2021  

To:

30 April 2022

Balance of unallotted securities under scheme(s) from previous return:

265,519

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

221,300

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

44,219

 

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 November 2021 

To:

30 April 2022

Balance of unallotted securities under scheme(s) from previous return:

3,069,147

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

1,695,652

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,373,495

 

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRMZGMKVMKGZZM